Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: myeloma patients + myeloma treatment + myeloma  Related to the article below (Last Update: 8/4/2008)

Treatment With Anti-anemia Drugs May Not Be Safe For Multiple ...
Science Daily (press release) -
In the study, 323 multiple myeloma patients were evaluated over a 20 year period in Greece from 1988 to 2007. The investigators reviewed their medical ...
New spots to cater to patients at campsite
Arkansas Democrat Gazette, AR -
The medical center, its Winthrop P. Rockefeller Cancer Institute and Myeloma Institute for Research and Therapy, are giving $ 90, 000 for construction of ...
Author : The Leukemia & Lymphoma Society
Earthtimes (press release), UK -
The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. ...
Long-term Effects of Thalomid? for Treatment of Myeloma Reported
Cancer Consultants, ID - Jul 30, 2008
It has now been 10 years since the introduction of Thalomid for the treatment of patients with relapsed or refractory myeloma. Researchers involved in the ...
How Molecules Out Of Balance Lead To Human Multiple Myeloma And ...
Science Daily (press release) - Jul 29, 2008
... myeloma and other B cell cancers, moving us closer to developing quick tests and readouts that could help in the tailored treatment of patients. ...
The Multiple Myeloma Research Consortium (MMRC) Announces the ...
MarketWatch - Jul 18, 2008
The Multiple Myeloma Research Consortium (MMRC), a 509a3 organization, was founded in 2004 by Kathy Giusti, a myeloma patient and Founder and Chief ...
Takeda/J&J: EU recommendation positions Velcade for first-line ...
Trading Markets (press release), CA - Jul 28, 2008
The drug is approved in the US, EU and Japan as a second-line treatment for multiple myeloma. It is also approved in the US as a second-line treatment for ...
Novartis's bone drug recommended for treatment of osteoporosis in men Trading Markets (press release)
all 4 news articles »  OTC:CMTX - JNJ - NVS

Fort Worth Business Press
Texas Oncology begins transplant outreach
Fort Worth Business Press, TX -
?I send him a lot of patients,? Ruxer said. ?A lot of patients I try to send him won?t go.? Patients with lymphoma, leukemia and multiple myeloma may ...
Results With Epratuzumab in Children With Acute Lymphoblastic ...
MarketWatch - Aug 1, 2008
... gemcitabine for pancreatic cancer therapy, and milatuzumab (anti-CD74 humanized antibody) as a therapy for patients with multiple myeloma, NHL, and CLL. ...
Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156 MarketWatch
all 21 news articles »
Celgene Corporation (NASDAQ:CELG) to Speak at Bank of America
TransWorldNews (press release), GA - Aug 1, 2008
THALOMID was approved by the FDA for treatment in combination with dexamethasone of patients with diagnosed multiple myeloma and is also approved for the ...CELG - BAC
Source: Google News

… . Correlation of measured myeloma cell mass with presenting clinical features, response to treatment …
BG Durie, SE Salmon - Cancer, 1975 - ncbi.nlm.nih.gov
... features, response to treatment, and survival. Durie BG, Salmon SE. The presenting
clinical features of 71 patients with multiple myeloma were correlated with ...

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
JR BERENSON, A LICHTENSTEIN, L PORTER, MA … - Journal of clinical oncology, 1998 - cat.inist.fr
Long-term pamidronate treatment of advanced multiple myeloma patients reduces
skeletal events. JR BERENSON, A LICHTENSTEIN, L PORTER ...

… acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or … -
LS Rosen, D Gordon, M Kaminski, A Howell, A Belch, … - Cancer J, 2001 - ncbi.nlm.nih.gov
... 9. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in
patients with breast cancer or osteolytic lesions of multiple myeloma: a phase ...

… treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group -
JR Berenson, A Lichtenstein, L Porter, MA … - Journal of Clinical Oncology, 1998 - jcojournal.org
... ARTICLES. Long-term pamidronate treatment of advanced multiple myeloma patients
reduces skeletal events. Myeloma Aredia Study Group. ...

… chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of … -
WM Gregory, MA Richards, JS Malpas - Journal of Clinical Oncology, 1992 - jco.ascopubs.org
... Pileri, and M. Boccadoro Dose-Intensive Melphalan With Stem Cell Support (MEL100)
Is Superior to Standard Treatment in Elderly Myeloma Patients Blood, August 15 ...

… conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma … -
DG Maloney, AJ Molina, F Sahebi, KE Stockerl- … - Blood, 2003 - ncbi.nlm.nih.gov
Click here to read Allografting with nonmyeloablative conditioning following
cytoreductive autografts for the treatment of patients with multiple myeloma. ...

Therapy with thalidomide in refractory multiple myeloma patients-the revival of an old drug. -
A Kneller, P Raanani, I Hardan, A Avigdor, I Levi, … - British Journal of Haematology, 2000 - pt.wkhealth.com
... for one patient, treatment was well tolerated with only mild side-effects. Thalidomide
should be included in the therapeutic options for refractory myeloma. ...

… disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or … -
LS Rosen, D Gordon, M Kaminski, A Howell, A Belch, … - Cancer, 2003 - doi.wiley.com
... each stratum. The median survival was longest for patients with multiple
myeloma ( 30 months for all treatment groups). Patients in ...

… Blood Stem Cell Transplantation in Multiple Myeloma: Up-front or Rescue Treatment? Results of a … -
JP Fermand, P Ravaud, S Chevret, M Divine, V … - Blood, 1998 - bloodjournal.hematologylibrary.org
... the mainstay of treatment in multiple myeloma (MM) has ... 1 With this treatment or other
standard-dose drug ... may reach 5 years only in selected responder patients. ...

… CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. -
PG Richardson, RL Schlossman, E Weller, T … - Blood, 2002 - ncbi.nlm.nih.gov
... Thal) can overcome drug resistance in multiple myeloma (MM) but is ... Therefore, 17
(71%) of 24 patients (90% CI, 52%-85%) demonstrated benefit from treatment. ...

Source: Google Scholar
 
 

Mayo Clinic Cancer Center -- Individualizing Treatment For Multiple Myeloma Patients

Article Date: 14 Dec 2006 - 10:00 PST
Researchers at Mayo Clinic Cancer Center, in cooperation with industry partners, have, for the first time, identified tumor specific alterations in the cellular pathway by which the multiple myeloma drug bortezomib (Velcade) works, and they have identified nine new genetic mutations in cancer cells that should increase a patient's chance of responding to the agent.

The investigators say these findings, presented Sunday, Dec. 10, at the 2006 American Society of Hematology Annual Meeting in Orlando, may help physicians tailor treatment to patients with multiple myleoma, a difficult-to-treat cancer of plasma cells that is the second most common blood cancer in the United States.

"Bortezomib seems to work in about one-third of patients who use it, but we have not been able to predict which ones," says the study's lead author, Leif Bergsagel, M.D., a hematologist at Mayo Clinic Arizona. "We now have identified a group that will likely respond because these nine mutations seem to be present in at least 25 percent of newly diagnosed patients.

Article continues below and (thank you)
 
"Now that we know the pathway the drug targets, and genetic mutations within this pathway that make patients respond better, we are working on a simple way to select those patients who are the best candidates for use of bortezomib," says Dr. Bergsagel.

In 2003, after only a four-month review, the Food and Drug Administration (FDA) approved use of bortezomib in patients who have failed other treatments for multiple myeloma. Later studies showed it lengthened survival by as much as six months. The drug was the first approved in a new class of agents known as proteasome inhibitors. Proteasomes are large protein groups inside cells that break down other proteins. Agents that inhibit the proteasome cause a buildup of proteins that affect many signaling cascades (various necessary biological processes). Bortezomib was initially thought to exert its activity by disrupting one of two known NF-�B (Nuclear Factor kappa B) pathways which keep cancer cells from self destructing the first-discovered, or canonical, NF-�B pathway.

But through extensive genetic examination of 42 unique multiple myeloma cell lines and tumor samples taken from 68 patients, the investigators defined multiple genetic mutations in the other NF-�B pathway, the so-called non-canonical pathway. "These mutations make the tumor more dependent on that pathway, and consequently more susceptible to bortezomib treatment," said senior author Rafael Fonseca, M.D., also at Mayo Clinic in Arizona.

"Identifying these mutations in patients will help us decide who should be treated with bortezomib, probably as an initial therapy," he says. The researchers are developing a test to check for activation of the non-canonical NF-eB pathway in patients.

Now that the mutations have been identified, drug designers may be able to fashion new therapies that are more specific to these genetic alterations and, therefore, less toxic,

Dr. Bergsagel says. "These mutations represent good targets for drug development," he says.

###

Other Mayo researchers involved in this study included Marta Chesi, Ph.D.; Scott Van Wier; Jonathan Keats, Ph.D.; Michael Sebag, M.D., Ph.D.; Wee-Joo Chng, M.D.; Roelandt Schop, M.D.; Homer Fogle III; Yuan Xiao Zhu Ph.D.; Chang-Xin Shi, Ph.D.; Tammy Price-Troska; Gregory Ahmann; Kim Henderson; Philip Greipp, M.D.; Angela Dispenzieri, M.D.; Keith Stewart, M.D.; and Rafael Fonseca, M.D. They collaborated with researchers John Carpten, Ph.D.; Angela Baker, Ph.D.; Tae-Hoon Chung, Ph.D.; Michael Barrett, Ph.D.; and Catherine Mancini from TGen, Phoenix, Ariz., and Laurakay Bruhn, Ph.D. from Agilent Labs, Santa Clara, Calif.

To find out more about treatment of blood diseases at Mayo Clinic visit http://www.mayoclinic.org/hematology-rst/treatmentgroups.html. Information regarding Mayo Clinic Cancer Center's related research is available online at http://cancercenter.mayo.edu/mayo/research/hematologic_malignancies.

Contact: Elizabeth Zimmermann
Mayo Clinic
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 
 © 2002-2006

Keywords::

Contact Iconocast

Home Page